Search

Your search keyword '"Mencinger, Marina"' showing total 41 results
Start Over Author "Mencinger, Marina"
41 results on '"Mencinger, Marina"'

1. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study

Author

Grande, Enrique, Arranz, José Á, De Santis, Maria, Bamias, Aristotelis, Kikuchi, Eiji, del Muro, Xavier Garcia, Park, Se Hoon, De Giorgi, Ugo, Alekseev, Boris, Mencinger, Marina, Izumi, Kouji, Schutz, Fabio A, Puente, Javier, Li, Jian-Ri, O'Donnell, Peter H, Kalebasty, Arash Rezazadeh, Ye, Dingwei, Mariathasan, Sanjeev, Bene-Tchaleu, FabioIa, Bernhard, Sandrine, Lee, Chooi, Davis, Ian D, and Galsky, Matthew D

Published
2024
Full Text
View/download PDF

2. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study

Author

Bamias, Aristotelis, Davis, Ian D, Galsky, Matthew D, Arranz, José Á, Kikuchi, Eiji, Grande, Enrique, del Muro, Xavier Garcia, Park, Se Hoon, De Giorgi, Ugo, Alekseev, Boris, Mencinger, Marina, Izumi, Kouji, Schutz, Fabio A, Puente, Javier, Li, Jian-Ri, Panni, Stefano, Gumus, Mahmut, Özgüroğlu, Mustafa, Mariathasan, Sanjeev, Poloz, Yekaterina, Bene-Tchaleu, Fabiola, Lee, Chooi, Bernhard, Sandrine, and De Santis, Maria

Published
2024
Full Text
View/download PDF

3. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Author

Buunk, Annemarie, Goossens, Hanneke, Baas, Gert, Algera, Maartje, Schuil-Vlassak, Evelyn, Ambagts, Thijs, De Hoog-Schouten, Leonie, Musaafir, Sara, Bosch, Roelof, Tjong, Carol, Steeman, Sanne, Van der Plas, Martine, Baldew, Glenn, Den Hollander, Iris, De Waal, Zacharias, Heijn, Aurele, Nelemans, Leen, Kouwen-Lubbers, Kirsten, Van Leeuwen, Maartje, Hoogenboom, Sacha, Van Doremalen, Jacobine, Ton, Célin, Beetstra, Bastien, Meijs, Veronique, Dikken, Jan, Dubero, Dasha, Slager, Mark, Houben, Tom, Kanis, Thomas, Overmars, Wietske, Nijenhuis, Marga, Steffens, Michael, Bergs, Ingmar, Karamperis, Kariofyllis, Siamoglou, Stavroula, Ivantsik, Ouliana, Samiou, Georgia-Chryssa, Kordou, Zoe, Tsermpini, Evira, Ferentinos, Panagiotis, Karaivazoglou, Aikaterini, Rigas, George, Gerasimou, Harilaos, Voukelatou, Georgia, Georgila, Eleni, Tsermpini, Evangelia Eirini, Mendrinou, Efrossyni, Chalikiopoulou, Konstantina, Kolliopoulou, Alexandra, Mitropoulos, Konstantinos, Stratopoulos, Apostolos, Liopetas, Ioannis, Tsikrika, Athina, Barba, Evangelia, Emmanouil, Georgia, Stamopoulou, Theano, Stathoulias, Andreas, Giannopoulos, Panagiotis, Kanellakis, Filippos, Bartsakoulia, Marina, Katsila, Theodora, Douzenis, Athanassios, Gourzis, Filippos, Assimakopoulos, Konstantinos, Bignucolo, Alessia, Dal Cin, Lisa, Comello, Francesco, Mezzalira, Silvia, Puglisi, Fabio, Spina, Michele, Foltran, Luisa, Guardascione, Michela, Buonadonna, Angela, Bartoletti, Michele, Corsetti, Serena, Ongaro, Elena, Da Ros, Lucia, Bolzonello, Silvia, Spazzapan, Simon, Freschi, Andrea, Di Nardo, Paola, Palazzari, Elisa, Navarria, Federico, Innocente, Roberto, Berretta, Massimiliano, D'Andrea, Mario, Angelini, Francesco, Diraimo, Tania, Favaretto, Adolfo, Dávila-Fajardo, Cristina Lucía, Díaz-Villamarín, Xando, Martínez-González, Luis Javier, Antúnez-Rodríguez, Alba, Moreno-Escobar, Eduardo, Fernández-Gómez, Ana Estefanía, García-Navas, Paloma, Bautista-Pavés, Alicia Bautista Pavés, Burillo-Gómez, Francisco, Villegas-Rodríguez, Inmaculada, Sánchez-Ramos, Jesús Gabriel, Antolinos-Pérez, Mª José, Rivera, Ricardo, Martínez-Huertas, Susana, Thomas-Carazo, Jesús, Yañez-Sanchez, Jose Julio, Blancas-López-Barajas, Mª Isabel, García-Orta, Rocío, González-Astorga, Beatriz, Rodríguez-González, Carlos José, Ruiz-Carazo, Francisco Javier, Pérez-Campos, Manuel, Cano-Herrera, Irene, Herrera, Rosa, Gil-Jiménez, Teresa, Delgado-Ureña, Mª Teresa, Triviño-Juarez, Jose Matías, Campos-Velázquez, Salustiano, Alcántara- Espadafor, Silvia, Moreno Aguilar, Maria Rosario, Ontiveros- Ortega, Maria Carmen, Carnerero-Córdoba, Lidia, Guerrero-Jiménez, Margarita, Legeren- Álvarez, Marta, Yélamos-Vargas, Marisol, Castillo-Pérez, Isabel, Aomar-Millán, Ismael, Anguita-Romero, Manuel, Sánchez-García, María José, Sequero-Lopez, Silvia, Faro-Miguez, Naya, López-Fernández, Silvia, Leyva-Ferrer, Rosario Nieves, Herrera-Gómez, Norberto, Pertejo-Manzano, Laura, Pérez-Gutierrez, Eva Mª, Martín-de la Higuera, Antonio J., Plaza-Carrera, Jose, Baena-Garzón, Flor, Toledo-Frías, Pablo, Cruz-Valero, Inés, Chacón-McWeeny, Verónica, Gallardo- Sánchez, Isabel, Arrebola, Antonio, Guillén-Zafra, Lucía, Ceballos-Torres, Ángel, Guardia-Mancilla, Plácido, Guirao-Arrabal, Emilio, Canterero-Hinojosa, Jesús, Velasco-Fuentes, Sara, Sánchez- Cano, Daniel, Aguilar-Jaldo, Mª del Pilar, Caballero-Borrego, Juan, Praznik, Monika, Slapšak, Urška, Voncina, Blaz, Rajter, Branka, Škrinjar, Andrej, Marjetic Ulcakar, Angelika, Zidanšek, Anja, Stegne Ignjatvic, Tea, Mazej Poredoš, Barbara, Vivod Pecnik, Živka, Poplas Susic, Tonka, Juteršek, Milojka, Klen, Jasna, Skoporc, Janja, Kotar, Tjaša, Petek Šter, Marija, Zvezdana Dernovšk, Mojca, Mlinšek, Gregor, Miklavcic, Petra, Plemenitaš Ilješ, Anja, Grašic Kuhar, Cvetka, Oblak, Irena, Stražišar, Branka, Štrbac, Danijela, Matos, Erika, Mencinger, Marina, Vrbnjak, Marko, Saje, Marko, Radovanovic, Mirjana, Jeras, Katja, Bukovec, Lucija, Terzic, Tea, Minichmayr, Iris, Nanah, Abdulaziz, Nielsen, Elisabet, Zou, Yuanxi, Lauschke, Volker, Johansson, Inger, Zhou, Yitian, Nordling, Åsa, Aigner, Christof, Dames-Ludwig, Marlies, Monteforte, Rossella, Sunder-Plassmann, Raute, Steinhauser, Corinna, Sengoelge, Guerkan, Winnicki, Wolfgang, Schmidt, Alice, Vasileios, Fragoulakis, Fontana, Vanessa, Hanson, Anita, Little, Margaret, Hornby, Rachael, Dello Russo, Cinzia, French, Stephanie, Hampson, Jamie, Gumustekin, Mukaddes, Anyfantis, George, Hampson, Lucy, Lewis, David, Westhead, Ruth, Prince, Clare, Rajasingam, Arjunan, Swen, Jesse J, van der Wouden, Cathelijne H, Manson, Lisanne EN, Abdullah-Koolmees, Heshu, Blagec, Kathrin, Blagus, Tanja, Böhringer, Stefan, Cambon-Thomsen, Anne, Cecchin, Erika, Cheung, Ka-Chun, Deneer, Vera HM, Dupui, Mathilde, Ingelman-Sundberg, Magnus, Jonsson, Siv, Joefield-Roka, Candace, Just, Katja S, Karlsson, Mats O, Konta, Lidija, Koopmann, Rudolf, Kriek, Marjolein, Lehr, Thorsten, Mitropoulou, Christina, Rial-Sebbag, Emmanuelle, Rollinson, Victoria, Roncato, Rossana, Samwald, Matthias, Schaeffeler, Elke, Skokou, Maria, Schwab, Matthias, Steinberger, Daniela, Stingl, Julia C, Tremmel, Roman, Turner, Richard M, van Rhenen, Mandy H, Dávila Fajardo, Cristina L, Dolžan, Vita, Patrinos, George P, Pirmohamed, Munir, Sunder-Plassmann, Gere, Toffoli, Giuseppe, and Guchelaar, Henk-Jan

Published
2023
Full Text
View/download PDF

4. Establishment of a virtual transborder tumor board for cancer patients in Central and Southeastern Europe: An initiative of the Central European Cooperative Oncology Group (CECOG)

Author

Thallinger, Christiane, Berzinec, Peter, Bicakcic, Emina, Dan, Adelina, Fabian, Gabriella, Gales, Laurentia Nicoletta, Kuhar, Cvetka Grasic, Janzic, Urska, Kahan, Zsusanna, Mencinger, Marina, Penthedourakis, George, Sgouros, Joseph, Simetic, Luka, Sirbu, Daniela, Vosmik, Milan, Wrona, Anna, and Zielinski, Christoph

Published
2022
Full Text
View/download PDF

5. Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice

Author

Mencinger Marina, Mangaroski Dusan, and Bokal Urska

Subjects
pd-l1 inhibitor, urothelial cancer, bladder, atezolizumab, overall survival, immune checkpoint inhibitor, prognostic factors, Medical physics. Medical radiology. Nuclear medicine, R895-920
Abstract

Atezolizumab, a programmed-death ligand-1 (PD-L1) inhibitor, is a novel treatment option for patients with metastatic urothelial cancer (mUC). Clinical prognostic factors, survival outcomes, and the safety of patients with mUC treated with atezolizumab, in a real-world setting, were investigated.

Published
2021
Full Text
View/download PDF

6. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

Author

Galsky, Matthew D, Arija, José Ángel Arranz, Bamias, Aristotelis, Davis, Ian D, De Santis, Maria, Kikuchi, Eiji, Garcia-del-Muro, Xavier, De Giorgi, Ugo, Mencinger, Marina, Izumi, Kouji, Panni, Stefano, Gumus, Mahmut, Özgüroğlu, Mustafa, Kalebasty, Arash Rezazadeh, Park, Se Hoon, Alekseev, Boris, Schutz, Fabio A, Li, Jian-Ri, Ye, Dingwei, Vogelzang, Nicholas J, Bernhard, Sandrine, Tayama, Darren, Mariathasan, Sanjeev, Mecke, Almut, Thåström, AnnChristine, and Grande, Enrique

Published
2020
Full Text
View/download PDF

8. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study

Author

Bamias, Aristotelis, primary, Davis, Ian D, additional, Galsky, Matthew D, additional, Arranz, José Á, additional, Kikuchi, Eiji, additional, Grande, Enrique, additional, del Muro, Xavier Garcia, additional, Park, Se Hoon, additional, De Giorgi, Ugo, additional, Alekseev, Boris, additional, Mencinger, Marina, additional, Izumi, Kouji, additional, Schutz, Fabio A, additional, Puente, Javier, additional, Li, Jian-Ri, additional, Panni, Stefano, additional, Gumus, Mahmut, additional, Özgüroğlu, Mustafa, additional, Mariathasan, Sanjeev, additional, Poloz, Yekaterina, additional, Bene-Tchaleu, Fabiola, additional, Lee, Chooi, additional, Bernhard, Sandrine, additional, and De Santis, Maria, additional

Published
2023
Full Text
View/download PDF

9. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study

Author

Grande, Enrique, primary, Arranz, José Á, additional, De Santis, Maria, additional, Bamias, Aristotelis, additional, Kikuchi, Eiji, additional, del Muro, Xavier Garcia, additional, Park, Se Hoon, additional, De Giorgi, Ugo, additional, Alekseev, Boris, additional, Mencinger, Marina, additional, Izumi, Kouji, additional, Schutz, Fabio A, additional, Puente, Javier, additional, Li, Jian-Ri, additional, O'Donnell, Peter H, additional, Kalebasty, Arash Rezazadeh, additional, Ye, Dingwei, additional, Mariathasan, Sanjeev, additional, Bene-Tchaleu, FabioIa, additional, Bernhard, Sandrine, additional, Lee, Chooi, additional, Davis, Ian D, additional, and Galsky, Matthew D, additional

Published
2023
Full Text
View/download PDF

10. Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma

Author

Grande, Enrique, primary, Bamias, Aristotelis, additional, Galsky, Matthew D., additional, Kikuchi, Eiji, additional, Davis, Ian D., additional, Arranz, José Ángel, additional, Rezazadeh Kalebasty, Arash, additional, Garcia del Muro, Xavier, additional, Park, Se Hoon, additional, De Giorgi, Ugo, additional, Alekseev, Boris, additional, Mencinger, Marina, additional, Izumi, Kouji, additional, Puente, Javier, additional, Li, Jian-Ri, additional, Bernhard, Sandrine, additional, Nicholas, Alan, additional, Telliez, Julie, additional, and De Santis, Maria, additional

Published
2023
Full Text
View/download PDF

12. Metastatski, na kastracijo odporen rak prostate

Author

Mencinger, Marina

Subjects
udc:616.6, onkološko zdravljenje, rak prostate, kemoterapija
Abstract

V pričujočem prispevku opisujemo zdravila z različnim mehanizmom delovanja: radij-223 (Ra-223), lutecij-177-PSMA-167 (Lu-177-PSMA), zaviralci imunskih nadzornih točk (ZINT) ter zaviralci poli-ADP-riboza polimeraze (PARP), ki so bila v zadnjih letih registrirana s strani ameriške in/ali evropske agencije za zdravila (angl. FDA, EMA) za zdravljenje bolnikov z metastatskim, na kastracijo odpornim rakom prostate (mKORP).

Published
2023

15. Final overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy (chemo) in untreated locally advanced or metastatic urothelial carcinoma (mUC) from the Phase 3 IMvigor130 study.

Author

Bamias, Aristotelis, primary, Davis, Ian D., additional, Galsky, Matt D., additional, Arranz Arija, Jose Angel, additional, Kikuchi, Eiji, additional, Grande, Enrique, additional, Garcia del Muro, Xavier, additional, Park, Se Hoon, additional, De Giorgi, Ugo, additional, Alekseev, Boris, additional, Mencinger, Marina, additional, Izumi, Kouji, additional, Puente, Javier, additional, Li, Jian-Ri, additional, Bene-Tchaleu, Fabiola, additional, Mariathasan, Sanjeev, additional, Lee, Chooi Peng, additional, Bernhard, Sandrine, additional, and De Santis, Maria, additional

Published
2023
Full Text
View/download PDF

16. Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem for first-line (1L) treatment (tx) of locally advanced or metastatic urothelial carcinoma (mUC): Final OS from the randomized Phase 3 IMvigor130 study.

Author

Galsky, Matt D., primary, Arranz Arija, Jose Angel, additional, De Santis, Maria, additional, Davis, Ian D., additional, Bamias, Aristotelis, additional, Kikuchi, Eiji, additional, Garcia del Muro, Xavier, additional, Park, Se Hoon, additional, De Giorgi, Ugo, additional, Alekseev, Boris, additional, Mencinger, Marina, additional, Izumi, Kouji, additional, Puente, Javier, additional, Li, Jian-Ri, additional, O'Donnell, Peter H., additional, Bernhard, Sandrine, additional, Lee, Chooi Peng, additional, Bene-Tchaleu, Fabiola, additional, Mariathasan, Sanjeev, additional, and Grande, Enrique, additional

Published
2023
Full Text
View/download PDF

17. Oligometastatski rak ledvic

Author

Mencinger, Marina

Subjects
udc:616-006, obsevanje, oligometastatski raki, sistemsko zdravljenje, onkološki bolniki
Published
2022

18. Establishment of a virtual transborder tumor board for cancer patients in Central and Southeastern Europe

Author

Thallinger, Christiane, Berzinec, Peter, Bicakcic, Emina, Dan, Adelina, Fabian, Gabriella, Gales, Laurentia Nicoletta, Kuhar, Cvetka Grasic, Janzic, Urska, Kahan, Zsusanna, Mencinger, Marina, Penthedourakis, George, Sgouros, Joseph, Simetic, Luka, Sirbu, Daniela, Vosmik, Milan, Wrona, Anna, and Zielinski, Christoph

Subjects
CECOG, Central and Southeastern Europe, Immune checkpoint inhibitors, Malignant diseases, Remote tumor board
Abstract

Purpose: To establish a transborder virtual tumor board (VTB) fostering state-of-the-art management of cancer patients by exchanging knowledge and expertise among oncologists in Central and Southeastern Europe (CEE). Methods: We established and implemented a VTB based on the WebEx platform. This allowed for password-protected and secure upload of patient cases to be presented and discussed among colleagues from various oncology centers scattered throughout CEE in order to arrive at a recommendation for further diagnoses and/or treatment. Results: A total of 73 cases from 16 oncology centers located in 11 CEE countries were uploaded by 22 physicians ; 71 were discussed over the course of 17 virtual meetings between June 2018 and May 2019 and 12 different kinds of malignant diseases were discussed with lung cancer (46.6%), melanoma (19.2%) and bladder cancer (13.6%) being the most commonly presented tumor entities. Of the discussed patients, 93.3% had stage IV disease at the time of presentation, 62.6% received chemotherapy or targeted treatment and 67.1% were treated with immune checkpoint inhibitors (ICPIs). The most common causes for presentation and discussion of patient cases were related to the use of ICPIs (80%). Conclusion: When the need for expertise exceeds locally available resources, web-based VTBs provide a feasible way to discuss patient cases and arrive at conclusions regarding diagnoses and/or treatment across large geographic distances. Moreover, VTBs provide an innovative way for proper, state-of-the-art management of patients with malignant diseases in times of social distancing and the resulting need for restricted interaction during the current SARS- CoV‑2 (severe acute respiratory syndrome coronavirus type 2) pandemic.

Published
2022

20. Overall survival (OS) by response during 'induction' from the global, randomized Phase III IMvigor130 study of atezolizumab (atezo) plus platinum/gemcitabine (plt/gem) vs placebo plus plt/gem in patients (pts) with previously untreated metastatic urothelial carcinoma (mUC)

Author

Grande, Enrique Bamias, Aristotelis Galsky, Matthew D. and Kikuchi, Eiji Davis, Ian D. Arranz, Jose Angel Kalebasty, Arash Rezazadeh Del Muro, Xavier Garcia Park, Se Hoon De Giorgi, Ugo Alekseev, Boris Mencinger, Marina Izumi, Kouji and Puente, Javier Li, Jian-Ri Shen, Xiaodong Ding, Beiying and Zhu, Qian Linsenmeier, Jeremy De Santis, Maria

Published
2021

21. Atezolizumab (atezo) monotherapy versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Clinical outcomes by PD-L1 status in cisplatin (cis)-ineligible pts from the phase III IMvigor130 study

Author

Galsky, Matt D. Bamias, Aristotelis Arranz Arija, Jose Angel and Davis, Ian D. De Santis, Maria Kikuchi, Eiji del Muro, Xavier Garcia Park, Se Hoon De Giorgi, Ugo Alekseev, Boris and Mencinger, Marina Izumi, Kouji Puente, Javier Li Jian-Ri and Mecke, Almut Mariathasan, Sanjeev Banchereau, Romain and Huang Xinhui Lee, Chooi Peng Grande, Enrique

Published
2021

22. Abstract CT187: Overall survival (OS) by response during “induction” from the global, randomized Phase III IMvigor130 study of atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with previously untreated metastatic urothelial carcinoma (mUC)

Author

Grande, Enrique, primary, Bamias, Aristotelis, additional, Galsky, Matthew D., additional, Kikuchi, Eiji, additional, Davis, Ian D., additional, Arranz, José Ángel, additional, Kalebasty, Arash Rezazadeh, additional, Garcia del Muro, Xavier, additional, Park, Se Hoon, additional, De Giorgi, Ugo, additional, Alekseev, Boris, additional, Mencinger, Marina, additional, Izumi, Kouji, additional, Puente, Javier, additional, Li, Jian-Ri, additional, Shen, Xiaodong, additional, Ding, Beiying, additional, Zhu, Qian, additional, Linsenmeier, Jeremy, additional, and De Santis, Maria, additional

Published
2021
Full Text
View/download PDF

23. Abstract CT040: Updated overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (mUC) in IMvigor130

Author

Davis, Ian D., primary, Galsky, Matthew D., additional, Garcia del Muro, Xavier, additional, Park, Se Hoon, additional, De Giorgi, Ugo, additional, Alekseev, Boris, additional, Mencinger, Marina, additional, Izumi, Kouji, additional, Puente, Javier, additional, Li, Jian-Ri, additional, Arranz, José Ángel, additional, Bamias, Aristotelis, additional, Grande, Enrique, additional, Kikuchi, Eiji, additional, Mecke, Almut, additional, Mariathasan, Sanjeev, additional, Shen, Xiaodong, additional, Huang, Hannah (Xinhui), additional, and De Santis, Maria, additional

Published
2021
Full Text
View/download PDF

24. Abstract CT042: Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Updated overall survival (OS) from the randomized phase III study IMvigor130

Author

Galsky, Matthew D., primary, Arranz, José Ángel, additional, Grande, Enrique, additional, De Santis, Maria, additional, Davis, Ian D., additional, Kikuchi, Eiji, additional, Garcia del Muro, Xavier, additional, Park, Se Hoon, additional, De Giorgi, Ugo, additional, Alekseev, Boris, additional, Mencinger, Marina, additional, Izumi, Kouji, additional, Puente, Javier, additional, Li, Jian-Ri, additional, O'Donnell, Peter H., additional, Shen, Xiaodong, additional, Lee, Chooi, additional, Mecke, Almut, additional, Mariathasan, Sanjeev, additional, and Bamias, Aristotelis, additional

Published
2021
Full Text
View/download PDF

26. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Author

Swen, Jesse J, van der Wouden, Cathelijne H, Manson, Lisanne EN, Abdullah-Koolmees, Heshu, Blagec, Kathrin, Blagus, Tanja, Böhringer, Stefan, Cambon-Thomsen, Anne, Cecchin, Erika, Cheung, Ka-Chun, Deneer, Vera HM, Dupui, Mathilde, Ingelman-Sundberg, Magnus, Jonsson, Siv, Joefield-Roka, Candace, Just, Katja S, Karlsson, Mats O, Konta, Lidija, Koopmann, Rudolf, Kriek, Marjolein, Lehr, Thorsten, Mitropoulou, Christina, Rial-Sebbag, Emmanuelle, Rollinson, Victoria, Roncato, Rossana, Samwald, Matthias, Schaeffeler, Elke, Skokou, Maria, Schwab, Matthias, Steinberger, Daniela, Stingl, Julia C, Tremmel, Roman, Turner, Richard M, van Rhenen, Mandy H, Dávila Fajardo, Cristina L, Dolžan, Vita, Patrinos, George P, Pirmohamed, Munir, Sunder-Plassmann, Gere, Toffoli, Giuseppe, Guchelaar, Henk-Jan, Buunk, Annemarie, Goossens, Hanneke, Baas, Gert, Algera, Maartje, Schuil-Vlassak, Evelyn, Ambagts, Thijs, De Hoog-Schouten, Leonie, Musaafir, Sara, Bosch, Roelof, Tjong, Carol, Steeman, Sanne, Van der Plas, Martine, Baldew, Glenn, Den Hollander, Iris, De Waal, Zacharias, Heijn, Aurele, Nelemans, Leen, Kouwen-Lubbers, Kirsten, Van Leeuwen, Maartje, Hoogenboom, Sacha, Van Doremalen, Jacobine, Ton, Célin, Beetstra, Bastien, Meijs, Veronique, Dikken, Jan, Dubero, Dasha, Slager, Mark, Houben, Tom, Kanis, Thomas, Overmars, Wietske, Nijenhuis, Marga, Steffens, Michael, Bergs, Ingmar, Karamperis, Kariofyllis, Siamoglou, Stavroula, Ivantsik, Ouliana, Samiou, Georgia-Chryssa, Kordou, Zoe, Tsermpini, Evira, Ferentinos, Panagiotis, Karaivazoglou, Aikaterini, Rigas, George, Gerasimou, Harilaos, Voukelatou, Georgia, Georgila, Eleni, Tsermpini, Evangelia Eirini, Mendrinou, Efrossyni, Chalikiopoulou, Konstantina, Kolliopoulou, Alexandra, Mitropoulos, Konstantinos, Stratopoulos, Apostolos, Liopetas, Ioannis, Tsikrika, Athina, Barba, Evangelia, Emmanouil, Georgia, Stamopoulou, Theano, Stathoulias, Andreas, Giannopoulos, Panagiotis, Kanellakis, Filippos, Bartsakoulia, Marina, Katsila, Theodora, Douzenis, Athanassios, Gourzis, Filippos, Assimakopoulos, Konstantinos, Bignucolo, Alessia, Dal Cin, Lisa, Comello, Francesco, Mezzalira, Silvia, Puglisi, Fabio, Spina, Michele, Foltran, Luisa, Guardascione, Michela, Buonadonna, Angela, Bartoletti, Michele, Corsetti, Serena, Ongaro, Elena, Da Ros, Lucia, Bolzonello, Silvia, Spazzapan, Simon, Freschi, Andrea, Di Nardo, Paola, Palazzari, Elisa, Navarria, Federico, Innocente, Roberto, Berretta, Massimiliano, D'Andrea, Mario, Angelini, Francesco, Diraimo, Tania, Favaretto, Adolfo, Dávila-Fajardo, Cristina Lucía, Díaz-Villamarín, Xando, Martínez-González, Luis Javier, Antúnez-Rodríguez, Alba, Moreno-Escobar, Eduardo, Fernández-Gonzalez, Ana Estefanía, García-Navas, Paloma, Bautista-Pavés, Alicia Bautista Pavés, Burillo-Gómez, Francisco, Villegas-Rodríguez, Inmaculada, Sánchez-Ramos, Jesús Gabriel, Antolinos-Pérez, Mª José, Rivera, Ricardo, Martínez-Huertas, Susana, Thomas-, Jesús, Carazo, Jose Julio, Yañez-Sanchez, Mª Isabel, Blancas-López-Navajas, Rocío, García-Orta, Beatriz, González-Astorga, Carlos José, Rodríguez-González, Francisco Javier, Ruiz-Carazo, Manuel, López-Pérez, Irene, Cano-Herrera, Rosa, Herrera, Teresa, Gil-Jiménez, Delgado-Ureña, Mª Teresa, Triviño-Juarez, Jose Matías, Campos-Velázquez, Salustiano, Alcántara-Espadafor, Silvia, Moreno Aguilar, Maria Rosario, Ontiveros-Ortega, Maria Carmen, Carnerero-Córdoba, Lidia, Guerrero-Jiménez, Margarita, Legeren-Álvarez, Marta, Yélamos-Vargas, Marisol, Castillo-Pérez, Isabel, Aomar-Millán, Ismael, Anguita-Romero, Manuel, Sánchez-García, María José, Sequero-Lopez, Silvia, Faro-Miguez, Naya, López-Fernández, Silvia, Leyva-Ferrer, Rosario Nieves, Herrera-Gómez, Norberto, Pertejo-Manzano, Laura, Pérez-Gutierrez, Eva Mª, Martín-de la Higuera, Antonio J., Plaza-Carrera, Jose, Baena-Garzón, Flor, Toledo-Frías, Pablo, Cruz-Valero, Inés, Chacón-McWeeny, Verónica, Gallardo-Sánchez, Isabel, Arrebola, Antonio, Guillén-Zafra, Lucía, Ceballos-Torres, Ángel, Guardia-Mancilla, Plácido, Guirao-Arrabal, Emilio, Canterero-Hinojosa, Jesús, Velasco-Fuentes, Sara, Sánchez-Cano, Daniel, Aguilar-Jaldo, Mª del Pilar, Caballero-Borrego, Juan, Praznik, Monika, Slapšak, Urška, Vončina, Blaz, Rajter, Branka, Škrinjar, Andrej, Marjetič Ulčakar, Angelika, Zidanšek, Anja, Stegne Ignjatvič, Tea, Mazej Poredoš, Barbara, Vivod Pečnik, Živka, Poplas Susič, Tonka, Juteršek, Milojka, Klen, Jasna, Skoporc, Janja, Kotar, Tjaša, Petek Šter, Marija, Zvezdana Dernovšk, Mojca, Klen, Jasna, Mlinšek, Gregor, Miklavčič, Petra, Plemenitaš Ilješ, Anja, Grašič Kuhar, Cvetka, Oblak, Irena, Stražišar, Branka, Štrbac, Danijela, Matos, Erika, Mencinger, Marina, Vrbnjak, Marko, Saje, Marko, Radovanovič, Mirjana, Jeras, Katja, Bukovec, Lucija, Terzič, Tea, Minichmayr, Iris, Nanah, Abdulaziz, Nielsen, Elisabet, Zou, Yuanxi, Lauschke, Volker, Johansson, Inger, Zhou, Yitian, Nordling, Åsa, Aigner, Christof, Dames-Ludwig, Marlies, Monteforte, Rossella, Sunder-Plassmann, Raute, Steinhauser, Corinna, Sengoelge, Guerkan, Winnicki, Wolfgang, Schmidt, Alice, Vasileios, Fragoulakis, Fontana, Vanessa, Hanson, Anita, Little, Margaret, Hornby, Rachael, Dello Russo, Cinzia, French, Stephanie, Hampson, Jamie, Gumustekin, Mukaddes, Anyfantis, George, Hampson, Lucy, Lewis, David, Westhead, Ruth, Prince, Clare, and Rajasingam, Arjunan

Abstract

The benefit of pharmacogenetic testing before starting drug therapy has been well documented for several single gene–drug combinations. However, the clinical utility of a pre-emptive genotyping strategy using a pharmacogenetic panel has not been rigorously assessed.

Published
2023
Full Text
View/download PDF

27. Atezolizumab (atezo) monotherapy versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Clinical outcomes by PD-L1 status in cisplatin (cis)-ineligible pts from the phase III IMvigor130 study.

Author

Galsky, Matt D., primary, Bamias, Aristotelis, additional, Arranz Arija, Jose Angel, additional, Davis, Ian D., additional, De Santis, Maria, additional, Kikuchi, Eiji, additional, Garcia del Muro, Xavier, additional, Park, Se Hoon, additional, De Giorgi, Ugo, additional, Alekseev, Boris, additional, Mencinger, Marina, additional, Izumi, Kouji, additional, Puente, Javier, additional, Li, Jian-Ri, additional, Mecke, Almut, additional, Mariathasan, Sanjeev, additional, Banchereau, Romain, additional, Huang, Xinhui, additional, Lee, Chooi Peng, additional, and Grande, Enrique, additional

Published
2021
Full Text
View/download PDF

30. Multidisciplinarna obravnava bolnikov z urogenitalnimi raki

Author

Borštnar, Simona, Čarman, Janka, Kragelj, Borut, Mencinger, Marina, Milanez, Tomaž, Šegedin, Barbara, Šeruga, Boštjan, Šešek, Manja, Škrbinc, Breda, and Zobec Logar, Helena Barbara

Subjects
udc:616.6, rak prostate, urogenitalni raki, rak mod, radioterapija, kirurgija, internistična onkologija
Published
2019

31. IMvigor130 clinical trial in patients (pts) with metastatic urothelial carcinoma (mUC): Analysis of upper tract (UT) and lower tract (LT) subgroups.

Author

De Santis, Maria, primary, Grande, Enrique, additional, Mencinger, Marina, additional, Li, Jian-Ri, additional, Puente, Javier, additional, Izumi, Kouji, additional, Lee, Jae-Lyun, additional, Kose, Fatih, additional, Antonyan, Igor, additional, Ding, Beiying, additional, Patel, Himika, additional, and Davis, Ian D., additional

Published
2020
Full Text
View/download PDF

32. Stranski učinki ob zdravljenju rakavih bolezni z zaviralci tirozinskih kinaz: Side effects of tyrosine kinase inhibitors in cancer treatment

Author

Mencinger, Marina

Abstract

Zaviralci tirozin-kinaz so multitarčna zdravila, ki prek zaviranja različnih celičnih procesov učinkujejo pri več vrstah rakavih boleznih. Čeprav so stranski učinki ob zaviralcih tirozinskih kinaz v splošnem prenosljivi, pa so lahko tudi resni in povzročajo nemalo preglavic bolnikom, ki prejemajo zdravila dolgotrajno. Pogosto je potrebno zmanjšanje odmerkov ali prehodna ukinitev, redkeje pa se odločimo za trajno prekinitev zdravljenja. Značilni so kožna toksičnost, kardiovaskularni zapleti, težave gastrointestinalnega trakta - predvsem diareja, nepravilno delovanje ščitnice in utrujenost ob zdravljenju rakave bolezni.

Published
2018

36. Preprečevanje bakterijskih in glivičnih okužb pri bolnikih z diseminiranim plazmocitomom, ki prejmejo ciklofosfamid za mobilizacijo krvotvornih matičnih celic: Antimicrobal and antifungal prophylaxis in patients with multiple myeloma, that receive cyclophosphamide for mobilization of hematopoietic stem cells

Author

Černelč, Peter and Mencinger, Marina

Abstract

Background Bacterial and fungal infections are the most common complication inpatients with hematological diseases treated with chemotherapy. Autologous hematopoietic stem cell transplantation is the most effective treatment of patients with multiple myeloma. Mobilization of hematopoietic stem cells (HSC), which allows collection of stem cells from peripheral venous blood, is induced by cyclophosphamide and granulocyte-colony stimulating factor (g-CSF).Cyclophosphamide is a toxic alkylating cytostatic agent that can causesevere neutropenia. Methods The purpose of this randomized retrospective study was to find out the efficacy of antimicrobal and antifungal prophylaxis with ciprofloxacine and fluconazole, respectively, in patients with multiple myeloma, that received cyclophosphamide (4g/m2) for mobilization of HSC. Results Altogether 112 myeloma patients that underwent autologous haematopoietic stem cell transplantation between years 2001-2007 were includedin the study. In the expected interval of neutropenia (from fifth day on after aplication of cyclophosphamide), 69 (62%) patients received ciprofloxacin, 34 (30%) patients also received fluconazole and 43 (55%) patients did not have any antimicrobal or antifungal prophylaxis. Leukopenia was found in 43 (55%) patients on the tenth day after administration of cyclophosphamide. Patients, who did not have any preventive treatment had approximately three times higher incidence of systemic infections. Etiology ofinfections was determined in only seven out of 23 patients. In one patient we suspected a respiratory tract infection with Aspergilus fumigatus. Conclusions Prophylaxis with ciprofloxacin in multiple myeloma patients, who receive cyclophosphamide for mobilization of haematopoetic blood cells, is warranted. On the contrary, prophylaxis with fluconazole does not seem to be necessary.

Published
2008

37. Genetsko testiranje za cistično fibrozo pri odraslih bolnikih: Genetic testing for cystic fibrosis in adult patients

Author

Korošec, Peter, Košnik, Mitja, Mencinger, Marina, and Šilar, Mira

Abstract

Background. Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in gene encoding cystic fibrosis transmembrane regulator (CFTR) protein. Over 1400 mutations found in the gene contribute to the complexity ofthe CF phenotypes ranging from a classic multiorgan disease commonly involving respiratory, gastrointestinal and reproductive tract to mild and monosymptomatic presentations. Pilocarpine iontophoresis is considered as standard diagnostic test for CF, but it often fails in atapical forms of CF. Methods. In order to provide an additional diagnostic test to assure the diagnosis and provide patients with a proper medical care, we performed a genetic testing on 16 adults suspected to have atypical form of CF. Following counselling, parents of patients with possible homozygote variant of mutationswere tested. On a personal request testing was also performed in an adult stibling of a patient with two known mutations to investigate possible carrier hood. The allele specific polymerase chain reaction method (PCR) was used to detected 29 most common mutations in the cftr gene. Results. the diagnosis was proved in 3 individuals, a homozygote for deltaF508, and two compound heterozygotes deltaF508/R1162X and deltaF508/3849+10kbC>T. In three cases only one mutation was found: I148T, 2789+5G>A and deltaF508 in a heterozygote form. Conclusions. The genetic testing for CF is a valuable diagnostic tool in atypical forms of CF. Exclusion of possible differential diagnosis is warranted because of a variable CF phenotype. In cases where onlyone or no mutation was detected a necessity of whole gene sequencing is indicated to exclude rare mutations and polymorphisms that could be implicatedin the pathogenesis of atypical CF.

Published
2006

38. Overall survival (OS) by response to first-line (1L) induction treatment with atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with metastatic urothelial carcinoma (mUC): Updated data from the IMvigor130 OS...

Author

Grande, Enrique, Bamias, Aristotelis, Galsky, Matt D., Kikuchi, Eiji, Davis, Ian D., Arranz, José A., Rezazadeh, Arash, Garcia del Muro, Xavier, Park, Se Hoon, De Giorgi, Ugo, Alekseev, Boris, Mencinger, Marina, Izumi, Kouji, Puente, Javier, Li, Jian-Ri, Lee, Chooi, Bernhard, Sandrine, Nicholas, Alan, Telliez, Julie, and De Santis, Maria

Published
2023
Full Text
View/download PDF

41. Expression Patterns of the Human Sarcoma-Associated GenesFUSandEWSand the Genomic Structure ofFUS

Author

Åman, Pierre, primary, Panagopoulos, Ioannis, additional, Lassen, Carin, additional, Fioretos, Thoas, additional, Mencinger, Marina, additional, Toresson, Håkan, additional, Höglund, Mattias, additional, Forster, Allan, additional, Rabbitts, Terence H., additional, Ron, David, additional, Mandahl, Nils, additional, and Mitelman, Felix, additional

Published
1996
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results